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Introduction
PPARγ is a member of  the nuclear hormone receptor superfamily. It is predominantly expressed in adi-
pose tissue and plays a role in adipogenesis as well as whole-body lipid metabolism and insulin sensi-
tivity (1, 2). The synthetic agonist rosiglitazone (RSG) has been successfully used in the clinical setting 
to treat type 2 diabetes by acting as an insulin sensitizer. However, adverse side effects, especially those 
observed in cardiac tissue, have seriously hindered its clinical application (3–6). Recent evidence has 
suggested that systemic activation of  PPARγ by thiazolidinediones induces cardiac hypertrophy in both 
mouse and rat models (7–11). Cardiac hypertrophy is an adaptive response, in which myocytes grow in 
length and/or width as a means to increase cardiac pump function and decrease ventricular wall tension 
(12). Mice overexpressing PPARγ in cardiomyocytes develop cardiomyopathy, suggesting that direct acti-
vation of  PPARγ in cardiomyocytes may lead to cardiac hypertrophy (13). However, there is evidence to 
suggest that systemic activation of  PPARγ by RSG is able to induce cardiac hypertrophy and oxidative 
stress in mice that lack PPARγ in cardiomyocytes (7, 14), implying that cardiac effects of  RSG may be 
partially independent of  PPARγ in cardiomyocytes. The foregoing implies that activation of  PPARγ in 
noncardiac tissue(s) may contribute to cardiac hypertrophy. However, the candidate tissue(s) responsible 
for RSG-induced cardiac hypertrophy is unknown.
Healthy adipose tissue plays a cardioprotective role, while dysfunctional adipose tissue may direct-
ly or indirectly contribute to cardiomyopathy, including ventricular dilation, myocyte hypertrophy, 
cardiac inflammation, and systolic dysfunction (15, 16). These data suggest a functional interplay 
between adipose and cardiac tissues. Given that adipose tissue is a major site of  PPARγ expression and 
function, it is possible that RSG-induced cardiac hypertrophy might be related to PPARγ activation in 
adipocytes. As well as being important for PPARγ signaling, adipose tissue plays critical roles as an 
Adipose tissue is a key endocrine organ that governs systemic homeostasis. PPARγ is a master 
regulator of adipose tissue signaling that plays an essential role in insulin sensitivity, making 
it an important therapeutic target. The selective PPARγ agonist rosiglitazone (RSG) has been 
used to treat diabetes. However, adverse cardiovascular effects have seriously hindered its 
clinical application. Experimental models have revealed that PPARγ activation increases cardiac 
hypertrophy. RSG stimulates cardiac hypertrophy and oxidative stress in cardiomyocyte-specific 
PPARγ knockout mice, implying that RSG might stimulate cardiac hypertrophy independently of 
cardiomyocyte PPARγ. However, candidate cell types responsible for RSG-induced cardiomyocyte 
hypertrophy remain unexplored. Utilizing cocultures of adipocytes and cardiomyocytes, we found 
that stimulation of PPARγ signaling in adipocytes increased miR-200a expression and secretion. 
Delivery of miR-200a in adipocyte-derived exosomes to cardiomyocytes resulted in decreased 
TSC1 and subsequent mTOR activation, leading to cardiomyocyte hypertrophy. Treatment with an 
antagomir to miR-200a blunted this hypertrophic response in cardiomyocytes. In vivo, specific 
ablation of PPARγ in adipocytes was sufficient to blunt hypertrophy induced by RSG treatment. By 
delineating mechanisms by which RSG elicits cardiac hypertrophy, we have identified pathways that 
mediate the crosstalk between adipocytes and cardiomyocytes to regulate cardiac remodeling.
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endocrine organ, secreting multiple cytokines to regulate systemic energy homeostasis, inflammation, 
and insulin resistance (17). Interestingly, a recent screen revealed that adipocytes are able to release 
microRNAs (miRNAs) (18).
miRNAs are a family of  highly conserved, small (~22 nucleotide) noncoding RNAs that posttranscrip-
tionally repress gene expression via degradation or translational inhibition of  their target mRNAs (19). 
Many miRNAs have been discovered to play key roles in cardiac remodeling, including miR-1 in attenuat-
ing agonist-induced hypertrophy, and miR-208 in promoting cardiac hypertrophy (20–22). In addition, car-
diac fibroblast–derived miR-21-3p was recently shown to mediate cardiomyocyte hypertrophy (23) through 
exosomes. The discovery of  circulating extracellular miRNAs in body fluids indicates a role for miRNAs 
in mediating cell-cell communication between tissues (24–26). Exosomes are the major transport vesicle of  
circulating miRNAs, allowing miRNA transfer and genetic exchange between cells (23, 27–30).
Given the potential interaction between adipose and cardiac tissue, we postulated that RSG might 
indirectly affect cardiac hypertrophy through PPARγ activation in adipocytes. Indeed, we found that RSG 
activation of  PPARγ signaling in adipocytes led to expression and secretion of  miR-200a in exosomes. 
Exosomes containing miR-200a targeted cardiomyocytes and specifically activated the mTOR pathway to 
induce cardiac hypertrophy.
Results
RSG regulates miR-200a levels in adipose and cardiac tissue by distinct mechanisms. As a ligand-activated nuclear 
receptor, PPARγ binds to PPAR response elements (PPREs) and regulates target gene expression. We ini-
tially took a bioinformatics approach to look at miRNA genes that could be potentially regulated by PPARγ. 
Our in silico analysis predicted that the miR-200 cluster contained 3 conserved PPREs in its upstream 
region (Supplemental Figure 2A; supplemental material available online with this article; doi:10.1172/jci.
insight.89908DS1). miR-200a was abundantly expressed in adipose tissue, while barely expressed in vessel, 
heart, or skeletal muscle (Supplemental Figure 1), exhibiting a similar expression pattern to that of  PPARγ 
(1, 2). To confirm our in silico findings, we performed chromatin immunoprecipitation assays. We found 
that PPARγ bound to PPRE1 (1,788 bp upstream of  transcription start site [TSS]) and PPRE2 (1,614 bp 
upstream of  TSS) (Supplemental Figure 2B) of  the miR-200a locus. These findings led us to hypothesize 
that PPARγ activation by RSG might regulate expression of  miR-200a. To assess this possibility, we treated 
WT mice with RSG (10 mg/kg/d) for 4 weeks and measured the expression of  miR-200a using real-time 
PCR. In adipose tissue, we found that both mature and primary transcripts of  miR-200a (pri-miR-200a) 
were increased following RSG treatment (Figure 1, A and B). However, in cardiac tissue, RSG treatment 
increased levels of  mature miR-200a, but not pri-miR-200a, implying that PPARγ activation modulated the 
levels of  miR-200a in adipose and cardiac tissue through distinct mechanisms (Figure 1, C and D).
To investigate whether increased levels of  mature miR-200a in cardiomyocytes were from an indi-
rect source, we treated isolated neonatal mouse cardiomyocytes with different concentrations of  RSG. 
Indeed, we found that RSG was unable to directly affect miR-200a levels in isolated cardiomyocytes, 
suggesting that increased miR-200a in the heart following systemic PPARγ activation by RSG originates 
from a noncardiomyocyte source (Figure 1E). We further investigated regulation of  miR-200a by RSG 
in cultured adipocytes. In 3T3-L1–differentiated adipocytes and primary mouse adult adipocytes, both 
mature and pri-miR-200a levels were significantly increased by RSG. To test the specific effect of  PPARγ 
Table 1. Echocardiographic measurements of Ctrl and AKO mice following RSG treatment for 4 weeks
BW (g) IVSd (mm) IVSs (mm) LVPWd (mm) LVPWs (mm) LVMd (mg) FS (%)
Ctrl + vehicle 23.4 ± 1.8 0.63 ± 0.02 0.92 ± 0.07 0.60 ± 0.02 1.05 ± 0.13 61.1 ± 11.0 34.7 ± 4.4
Ctrl + RSG 23.8 ± 1.1 0.74 ± 0.08A 1.08 ± 0.10 A 0.69 ± 0.06 A 1.11 ± 0.03 87.4 ± 7.2 A 32.2 ± 3.4
AKO + vehicle 25.5 ± 2.2 0.69 ± 0.07 0.96 ± 0.08 0.64 ± 0.06 1.05 ± 0.07 74.4 ± 11.1 31.1 ± 5.1
AKO + RSG 23.3 ± 1.8 0.69 ± 0.05 1.02 ± 0.09 0.68 ± 0.05 1.12 ± 0.06 71.1 ± 8.6 41.3 ± 7.0
AKO, adipocyte-specific PPARγ knockout mice; Ctrl, littermate control mice; FS, fractional shortening; IVSd, interventricular septal thickness in end-
diastole; IVSs, interventricular septal thickness in end-systole; LVMd, left ventricle mass in end-diastole; LVPWd, left ventricular diastolic posterior 
wall thickness; LVPWs, left ventricular systolic posterior wall thickness; RSG, rosiglitazone. n = 5–8 mice per group. Data are represented as mean ± 
SEM; AP < 0.05 vs. Ctrl + vehicle, according to 2-tailed Student’s t test.
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activation, we pretreated adipocytes with the PPARγ antagonist GW9662. As expected, we found that 
the PPARγ antagonist was sufficient to abrogate increases in both mature miR-200a and pri-miR-200a 
levels in response to RSG treatment in adipocytes (Figure 1, F and G). Together, these results suggested 
that PPARγ activation by RSG might directly induce miR-200a transcription in adipocytes, potentially 
indirectly leading to an increase in miR-200a levels in cardiomyocytes.
Exosomes transport miR-200a from adipocytes to cardiomyocytes. Recent studies have revealed that miRNAs 
can circulate and be delivered to recipient cells via exosomes, targeting gene expression in recipient cells 
(28–31). We hypothesized that RSG might increase miR-200a in the heart through circulating exosomes 
derived from adipose tissues. In support of  this, we detected elevated levels of  miR-200a in sera from mice 
treated with RSG (Figure 2A). Furthermore, we observed a 3- to 5-fold increase in levels of  mature miR-
200a in culture media from adipocytes treated with RSG (Figure 2B). The effect of  RSG was blunted when 
the cells were pretreated with the PPARγ antagonist GW9662. To test whether miR-200a was transported 
in exosomes, we used an exosome biogenesis inhibitor, GW4869, in combination with RSG to see whether 
miR-200a levels in adipocyte culture media would be affected. As predicted, by inhibiting exosome biosyn-
thesis, we found reduced levels of  secreted miR-200a in adipocyte culture media (Figure 2B).
To further characterize miRNA-containing exosomes produced by adipocytes in vitro, we performed 
transmission electron microscopy (TEM) of  isolated exosomes (Figure 2C). TEM revealed that the diam-
eter of  exosomes was heterogeneous, but the majority of  exosomes had diameters of  between 60 and 
100 nm. In addition to TEM, we also analyzed the contents of  isolated exosomes and found that they 
contained elevated levels of  miR-200a when adipocytes were treated with RSG (Figure 2D). Importantly, 
Figure 1. Regulation of miR-200a expression by rosiglitazone. (A–D) WT mice were treated for 4 weeks with either rosiglitazone (RSG) or vehicle 
(control). Levels of mature miR-200a and primary transcript of miR-200a (pri-miR-200a) were quantified using quantitative real-time PCR (qRT-
PCR) in adipose (A and B) and cardiac tissue (C and D), respectively. Note that miR-200a and pri-miR-200a levels are both increased in RSG-treated 
adipose tissue, but only mature miR-200a is upregulated in cardiac tissue. n = 5 mice. (E–G) Cells were treated with RSG alone, RSG combined with 
GW9662 (PPARγ antagonist), or DMSO (control). Levels of mature miR-200a and pri-miR-200a were quantified using qRT-PCR. (E) Expression levels 
of miR-200a were measured in cardiomyocytes. Note that miR-200a is not induced in cardiomyocytes by RSG at varying concentrations after 24, 36, 
and 48 hours of treatment. The experiment was replicated 3 times. (F and G) Expression levels of miR-200a and pri-miR-200a were quantified in 
3T3-L1–induced adipocytes and primary adipocytes treated with RSG alone, RSG combined with GW9662, or DMSO (control). Note that RSG increases 
both mature miR-200a and pri-miR-200a levels (F and G, respectively) in both cell types, but the effect is ablated when RSG is combined with the 
PPARγ antagonist GW9662. The experiment was replicated 3 times. snoRNA 202 and Gapdh were used as internal controls for qRT-PCR experiments. 
Data are represented as mean ± SEM; *P < 0.05 according to 2-tailed Student’s t test for A–D and 1-way ANOVA for E–G.
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increased levels of  miR-200a in response to RSG were attenu-
ated by addition of  the PPARγ agonist GW9662.
Our earlier observations suggested that increased miR-200a 
in cardiac tissue was through an indirect mechanism (Figure 
1, C and D). To test whether miR-200a could be from adipo-
cyte-derived exosomes, we transfected a synthetic miR-200a 
(a 22-oligomer labeled with Cy3 fluorophore [Cy3-miR-200a]) 
into 3T3-L1–differentiated adipocytes. Exosomes from adipo-
cyte culture media were collected after 24 hours and were used 
to treat cultured cardiomyocytes. As expected, we were able to 
detect Cy3-miR-200a in cardiomyocytes (Figure 2E). Incuba-
tion of  cardiomyocytes with exosomes derived from adipocytes 
treated with RSG led to increased levels of  miR-200a in cardio-
myocytes. The effect was abrogated by GW9662 (Figure 2F). 
Taken together, these results suggested that adipocytes secreted 
miR-200a–containing exosomes could be delivered into cardio-
myocytes, likely accounting for the increased level of  mature 
miR-200a in the cardiomyocytes.
Exosomes transport functional miR-200a from adipocytes to car-
diomyocytes. After establishing that purified exosomes containing 
miR-200a could be taken up by cardiomyocytes, we next wanted 
to establish a more in vivo–like situation in which we could cocul-
ture adipocytes with cardiomyocytes. In this setup, 3T3-L1 cells 
were seeded and induced to become adipocytes, followed by the 
addition of  mouse neonatal cardiomyocytes in a Transwell cham-
ber above the adipocytes (Figure 3A). The two cell types were 
separated by a membrane with a 0.4-μm pore size to prevent cell-
cell contact or transfer of  vesicles larger than 0.4 μm. First, we 
transfected adipocytes with Cy3-miR-200a and analyzed the Cy3 
fluorescence in cardiomyocytes after 24 hours of  coculture. In 
agreement with our earlier observations, we found that Cy3-miR-
200a was indeed able to be transferred from adipocytes to cardio-
myocytes during coculture (Figure 3C). Furthermore, to confirm 
that adipocytes were able to secrete miRNAs in exosomes that 
would subsequently be taken up by cardiomyocytes, we transfect-
ed adipocytes with a miRNA that is only naturally expressed in 
Caenorhabditis elegans (cel-miR-39). Analysis of  cel-miR-39 levels 
in cardiomyocytes after transfection demonstrated that cardiomy-
ocytes could take up cel-miR-39 from adipocytes. By using the 
exosome biogenesis inhibitor GW4869 we were able to attenuate 
the transfer of  cel-miR-39 from adipocytes to cardiomyocytes, 
which was consistent with our earlier observations (Figure 3B).
To demonstrate that adipocytes were the source of  miR-
200a, we cultured cardiomyocytes in the presence or absence of  
adipocytes and added RSG to the culture media. In the absence 
of  adipocytes, we observed no increase in miR-200a levels, 
consistent with our previous finding (Figure 1E). However, we 
observed a dramatic increase in cardiomyocyte miR-200a lev-
els by RSG stimulation when cocultured with adipocytes. This 
effect could be inhibited by pretreating adipocytes with either 
the PPARγ antagonist GW9662 or the exosome biogenesis 
inhibitor GW4869. Unchanged pri-miR-200a levels in cardio-
myocytes following treatment with RSG further confirmed that 
adipocytes were the source of  miR-200a (Figure 3E).
Figure 2. Exosome-dependent miR-200a secretion from adipocytes. (A) The 
levels of miR-200a were quantified using quantitative real-time PCR (qRT-
PCR) in sera from mice treated with rosiglitazone (RSG) or vehicle (control). 
Note that miR-200a was increased after RSG treatment, but not in the 
vehicle control. n = 5 mice. (B) Expression levels of miR-200a were quanti-
fied using qRT-PCR in culture media from either 3T3-L1–induced adipocytes 
or mouse primary adipocytes treated with RSG alone, RSG and GW9662 
(PPARγ antagonist), RSG and GW4869 (exosome biogenesis inhibitor), or 
DMSO (control). Note that RSG increased miR-200a levels in the culture 
media, but this effect was ablated when cells were treated with either 
PPARγ antagonist or exosome biogenesis inhibitor. The experiment was 
replicated 3–6 times. (C) Representative transmission electron micrographs 
of adipocyte-derived exosomes. The experiment was replicated 3 times. 
Scale bar: 50 nm. (D) Levels of miR-200a in exosomes were quantified using 
qRT-PCR from culture media of adipocytes treated with RSG alone, RSG 
and GW9662 (PPARγ antagonist), or DMSO (control). Note the increase in 
exosomal miR-200a levels when adipocytes were treated with RSG, but this 
effect was ablated when adipocytes were treated with PPARγ antagonist. 
The experiment was replicated 3 times. (E) Cardiomyocytes were incubated 
with exosomes derived from 3T3-L1 cells transfected with Cy3-conjugated 
miR-200a and were subsequently fixed and imaged. DAPI is depicted in blue; 
Cy3-miR-200a in red. Note that cardiomyocytes took up the miR-200a–con-
taining exosomes. The experiment was replicated 3 times. Scale bar: 20 μm. 
(F) Levels of miR-200a were quantified using qRT-PCR of cardiomyocytes 
that were incubated with exosomes derived from treated adipocytes, as in D. 
Note that levels of miR-200a in cardiomyocytes increased after incubation 
with exosomes derived from RSG-treated adipocytes, but levels were not 
increased after incubation with exosomes derived from adipocytes treated 
with RSG and PPARγ antagonist. The experiment was replicated 3 times. 
snoRNA 202 and cel-miR-39 were used as internal controls for qRT-PCR 
experiments. Data are represented as mean ± SEM; *P < 0.05 according to 
2-tailed Student’s t test for A and 1-way ANOVA for B, D, and F.
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After establishing the source of  miR-200a, we deter-
mined whether secreted miR-200a was functional. We 
transfected H9C2 cells with a miR-200a reporter vector, 
consisting of  4 seed-binding sequences in the 3ˇ-UTR 
of  a luciferase reporter gene. A reduction in luciferase 
activity is indicative of  functional miR-200a, as miR-
200a binds to the 3ˇ-UTR of  luciferase and decreases its 
expression. Transfected H9C2 cells were seeded in the 
presence and absence of  adipocytes, and luciferase activ-
ity in H9C2 cells was monitored after 72 hours. Lucifer-
ase activity in H9C2 cells was substantially reduced only 
following coculture with adipocytes. As expected, RSG 
treatment led to a further reduction in luciferase activity. 
This effect could be attenuated by pretreating adipocytes 
with the exosome biogenesis inhibitor GW4869 (Figure 
3D) or by the PPARγ antagonist GW9662 (Figure 3F). 
In summary, these results demonstrated that functional 
mature miR-200a is packaged in secretory exosomes that 
could be transferred from adipocytes to cardiomyocytes 
to mediate gene silencing.
Adipocyte-derived miR-200a induces cardiomyocyte hyper-
trophy in vitro. Recent evidence shows that RSG treatment 
results in cardiac hypertrophy in both mouse and rat mod-
els (7–11). Given our data that show that RSG treatment 
leads to the secretion of  functionally active miR-200a from 
adipocytes to cardiomyocytes, we hypothesized that miR-
200a might target specific genes in cardiomyocytes that 
regulate cardiac hypertrophy. To uncover potential miR-
200a target genes involved in cardiac hypertrophy, we took 
a bioinformatic approach to reveal TSC1 as a putative can-
didate gene (Figure 4A). TSC1 has previously been shown 
to regulate cardiomyocyte size and cardiac remodeling 
through the mTOR pathway (32–34). Specifically, mice 
that have had TSC1 ablated in cardiomyocytes develop 
cardiac hypertrophy that leads to heart failure. This effect 
can be rescued by treating mice with the mTOR inhibitor 
rapamycin (35). TSC1 combines with TSC2 and functions 
as a GAP. The GTP-bound form of the G protein Rheb 
activates mTOR, and the TSC1/TSC2 complex converts 
Rheb to the GDP-bound form, thus inhibiting activation 
of  mTOR (32). RSG-induced heart remodeling is associ-
ated with mTOR activation (10). We hypothesized that, 
if  TSC1 were a target of  miR-200a, a consequent reduc-
tion in GAP activity of  the TSC1/TSC2 complex would 
lead to increased activation of  Rheb and subsequent acti-
vation of  the hypertrophic mTOR pathway in cardiomy-
ocytes. To test whether TSC1 was a target of  miR-200a, 
we constructed a luciferase reporter construct conjugated 
to the 3ˇ-UTR region of  TSC1 (Figure 4A). We cotrans-
fected 293 cells with the reporter construct, a miR-200a 
mimic, or scrambled control. Only cotransfection with the 
miR-200a mimic reduced luciferase activity, showing that 
miR-200a was able to specifically target TSC1 (Figure 4B). 
Next, we wanted to test the potential biological function 
Figure 3. miR-200a is transported from adipocytes to cardiomyocytes in exosomes. 
(A) An in vitro coculture system was used in which cardiomyocytes are seeded in the 
top compartment, which is separated by a porous membrane from adipocytes that are 
cultured in the bottom of the plate. (B) Adipocytes were transfected with Cy3-miR-
200a and cocultured with cardiomyocytes. After 24 hours, cardiomyocytes were fixed 
and imaged. DAPI is depicted in blue; Cy3-miR-200a in red. Note that the cardio-
myocytes were able to take up the Cy3-conjugated miR-200a. The experiment was 
replicated 3 times. Scale bar: 20 μm. (C) Adipocytes were transfected with cel-miR-39 
or not transfected (control) and subsequently seeded in the bottom compartment, as 
shown in A. RNA was isolated from cardiomyocytes at the indicated times after the 
start of the coculture. The levels of cel-miR-39 were quantified using quantitative 
real-time PCR (qRT-PCR). Note that cel-miR-39 was found in cardiomyocytes at 1 hour 
and 24 hours after coculture, and levels of cel-miR-39 were decreased when exosome 
biogenesis was inhibited by GW4869. The experiment was replicated 3 times. (D and 
E) Primary adipocytes were treated with rosiglitazone (RSG) alone, RSG and GW9662, 
or RSG and GW4869. Cardiomyocytes were subsequently cocultured in the presence 
or absence of the primary adipocytes for 48 hours. Expression levels of miR-200a (D) 
and pri-miR-200a (E) in cardiomyocytes were quantified using qRT-PCR. Note that 
mature miR-200a levels were increased only in cardiomyocytes that were cocultured 
in the presence of adipocytes. Pretreatment of adipocytes with RSG further augment-
ed the levels of mature miR-200a. Importantly, this effect was rescued by treating 
cells with either PPARγ antagonist or exosome biogenesis inhibitor. The experiment 
was replicated 3 times. (F) Primary adipocytes were treated with RSG alone, RSG and 
GW9662, or RSG and GW4869. H9C2 cells were transfected with a miR-200a luciferase 
reporter construct and subsequently seeded in the upper compartment of the plate, 
as depicted in A. Luciferase activity of H9C2 cells was quantified after 48 hours of 
coculture. Note that luciferase levels were reduced in H9C2 cells when cocultured with 
adipocytes. This effect was exacerbated when adipocytes were pretreated with RSG 
and was rescued by treating cells with the PPARγ antagonist GW9662 and exosome 
biogenesis inhibitor GW4869. The experiment was replicated 3 times. snoRNA 202 
was used as internal controls for qRT-PCR experiments. Data are represented as mean 
± SEM; *P < 0.05 according to 1-way ANOVA.
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of miR-200a on TSC1 levels and mTOR signaling in cardiomyocytes. Given the low transfection efficiency 
observed with cardiomyocytes using conventional transfection methods, we generated miR-200a and GFP 
(control) adenoviruses. Thirty-six hours following viral infection, levels of  TSC1 and both total and phos-
phorylated mTOR were quantified. miR-200a overexpression marked reduced protein levels of  TSC1 and 
increased mTOR phosphorylation (Figure 4C). Furthermore, when cardiomyocyte size was measured, cells 
overexpressing miR-200a were significantly larger than control GFP-treated counterparts (Figure 4, D and 
E). This effect was dependent on mTOR signaling, because treatment with the mTOR inhibitor rapamycin 
rendered cells insensitive to miR-200a–induced hypertrophy (Figure 4, D and E). Cardiac remodeling is often 
accompanied by reexpression of  a fetal gene program (12). Indeed, both atrial natriuretic peptide (Anp) and 
B-type natriuretic peptide (Bnp) levels significantly increased when cardiomyocytes were treated with miR-
200a. Treatment with the mTOR inhibitor rapamycin was sufficient to block the response of  cardiomyocytes 
to miR-200a–induced hypertrophy (Figure 4, F and G).
After establishing that miR-200a was able to affect TSC1 levels and mTOR signaling in isolated 
cardiomyocytes, we sought next to identify whether miR-200a secreted from adipocytes could have 
similar functional consequences in cardiomyocytes. To study this, we employed our coculture system 
to study effects of  RSG-treated adipocytes on cardiomyocytes and found that RSG-treated adipocytes 
Figure 4. miR-200a activates the mTOR pathway to promote cardiomyocyte hypertrophy. (A) Comparison of the seed region of miR-200a with putative 
target sequences of the 3ˇ-UTR conserved regions in human, chimpanzee, mouse, rat, dog, and chicken TSC1 mRNA. (B) HEK293 cells were cotransfected 
with either miR-200a mimic or scrambled RNA oligo (control) in combination with a TSC1 3ˇ-UTR-luciferase reporter construct. Note that the luciferase 
activity was significantly reduced in cells expressing the miR-200a mimic compared with the control RNA oligo. The experiment was replicated 3 times. 
(C) Neonatal rat cardiomyocytes were infected with miR-200a or GFP (control) adenovirus, and the levels of phosphorylated mTOR (S2448), total mTOR, 
and TSC1 were detected. Note that the levels of phosphorylated mTOR increased and the levels of TSC1 decreased in miR-200a–overexpressing cells. The 
experiment was replicated 3 times. (D and E) Neonatal rat cardiomyocytes were infected with miR-200a or GFP (control) adenovirus, as in C, and were 
subsequently treated with or without rapamycin. Cells were fixed and stained for DNA using DAPI (blue) and Phalloidin (red) after 36 hours. Note that cell 
size increased when infected with miR-200a adenovirus, and this effect was reversible when cells were treated with the mTOR inhibitor rapamycin (Rapa). 
The experiment was replicated 3 times. Scale bar: 10 μm. (F and G) Neonatal rat cardiomyocytes were infected with miR-200a or GFP (control) adenovirus, 
as in C, and were treated with or without rapamycin. RNA was isolated from cells and levels of cardiac hypertrophy markers atrial natriuretic peptide (Anp) 
and B-type natriuretic peptide (Bnp) were quantified using quantitative real-time PCR. Note that levels of both Anp and Bnp increased when cells were 
infected with miR-200a, and this was reversible when treated with rapamycin. The experiment was replicated 5 times. Data are represented as mean ± 
SEM; *P < 0.05 according to 2-tailed Student’s t test for B and 1-way ANOVA for E–G.
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reduced levels of  TSC1 and increased mTOR activity in cardiomyocytes (Figure 5A). These effects were 
abrogated by treatment with either the PPARγ antagonist GW9662 or the exosome biogenesis inhibitor 
GW4869. To confirm that cardiomyocytes were actively undergoing remodeling, we examined the cell 
size and levels of  Anp and Bnp in the presence and absence of  adipocytes. As expected, the cell size and 
levels of  both were elevated only when cardiomyocytes were cocultured with adipocytes (Figure 5, B–D). 
RSG treatment further increased the cell size and the levels of  Anp and Bnp, and this effect was attenuat-
ed either by antagonism of  PPARγ signaling or inhibition of  exosome biogenesis.
To evaluate the functional role of  adipocyte-derived miR-200a in promoting hypertrophy in cardiomy-
ocytes, we used a miR-200a antagomir to specifically inhibit miR-200a function. Adipocytes were trans-
fected with a miR-200a antagomir (Figure 5, E and F), or cardiomyocytes were infected with a miR-200a 
Figure 5. Adipocyte-derived miR-200a mediates cardiomyocyte hypertrophy in vitro. (A) Primary adipocytes were treated with rosiglitazone (RSG) 
alone, RSG and GW9662 (PPARγ antagonist), or RSG and GW4869 (exosome biogenesis inhibitor). Cardiomyocytes were subsequently cocultured in the 
presence or absence of the primary adipocytes for 72 hours, as in Figure 4A. Cardiomyocytes were subsequently lysed, and Western blots were performed. 
Note that in the absence of adipocytes, levels of TSC1, total mTOR, and phosphorylated mTOR in cardiomyocytes were unaffected when treated with RSG. 
Conversely, in the presence of adipocytes, RSG activated mTOR signaling and decreased protein levels of TSC1. Importantly, this effect was rescued using 
either PPARγ antagonist or exosome biogenesis inhibitor. The experiment was replicated 4 times. (B–D) Adipocytes and cardiomyocytes were cocultured 
and treated as in A, and RNA was subsequently extracted after 72 hours. The cell size and levels of atrial natriuretic peptide (Anp) and B-type natriuretic 
peptide (Bnp) in cardiomyocytes were quantified. Note that the cell size and levels of Anp and Bnp increased when cocultured with adipocytes, and this 
effect was exacerbated when treated with RSG. This effect was rescued by treating adipocytes with PPARγ antagonist and exosome biogenesis inhibitor. 
The experiment was replicated 3–5 times. (E and F) 3T3-L1-induced adipocytes were transfected with either miR-200a antagomir or control RNA for 24 
hours followed by treatment with RSG or DMSO (control). Cardiomyocytes were subsequently cocultured, and RNA was extracted and quantified using 
quantitative real-time PCR after 72 hours of coculture. Note that the increased levels of Anp and Bnp were ablated when adipocytes were treated with 
miR-200a antagomir. The experiment was replicated 3 times. (G and H) Rat cardiomyocytes were infected with miR-200a antagomir or control RNA for 
24 hours before being adenovirus cocultured with adipocytes. Adipocytes were treated with RSG and RNA was isolated from cardiomyocytes. Note the 
increased levels of Anp and Bnp were ablated when cardiomyocytes were treated with miR-200a antagomir. The experiment was replicated 3 times. Data 
are represented as mean ± SEM; *P < 0.05 according to 1-way ANOVA.
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antagomir–expressing adenovirus (Figure 5, G and H). Cells were then cocultured and treated with RSG. 
In both cell types, treatment with the miR-200a antagomir abolished effects of  RSG on cardiac hypertrophy 
markers Anp and Bnp, indicating that RSG acted through miR-200a to induce cardiomyocyte hypertrophy. 
Taken together, these data suggested that miR-200a was necessary and sufficient to target TSC1 in cardio-
myocytes, leading to stimulation of  the mTOR pathway and cardiomyocyte hypertrophy.
RSG-induced cardiac hypertrophy is attenuated in mice with PPARγ-deficient adipocytes. To test our hypothesis 
that RSG activates PPARγ signaling in adipocytes, leading to secretion of  miR-200a–containing exosomes, 
which in turn induces cardiomyocyte hypertrophy, we used an adipose-specific PPARγ knockout mouse 
(AKO mouse), utilizing Fabp4-Cre and a floxed allele of  PPARγ. We treated mice with RSG for 4 weeks 
and assessed levels of  PPARγ target genes in cardiac and adipose tissue. RSG was able to induce known 
target genes Ap2 and Cd36 in cardiac tissue of  AKO mice; however,RSG failed to induce target gene expres-
sion in adipose tissue, demonstrating the specificity of  the knockout (Supplemental Figure 3, A–D). Histo-
logical analyses and measurement of  left ventricle weight/body weight ratios and left ventricle weight/tibia 
length ratios revealed a blunted hypertrophic response to RSG in AKO mice when compared with control 
mice (Figure 6, A–C), supporting our in vitro observations. Further echocardiographic analysis following 
Figure 6. Rosiglitazone-induced cardiac hypertrophy is attenuated in mice with PPARγ-deficient adipocytes. Adipose-specific PPARγ knockout 
(AKO) and littermate control mice (Ctrl) were treated with rosiglitazone (RSG) to induce cardiac hypertrophy. (A) Representative whole-mouse heart 
(top) and H&E-stained sections (bottom). Scale bar: 2 mm. n = 3 mice per group. (B and C) The ratios of left ventricle weight (LV) to body weight (BW) 
and LV to tibia length (TL) were measured. Note that both ratios increased in the control mice; however, the effect was blunted in the AKO mice. n 
= 5–8 mice. (D and E) Echocardiography revealed thicknesses of the interventricular septum (IVSd) and left ventricular posterior wall (LVPWd). Note 
that both septal and posterior wall thicknesses increased in the control mice, but this effect was not observed in AKO mice. n = 5–8 mice. (F and G) 
RNA from the left ventricle was extracted, and levels of atrial natriuretic peptide (Anp) and B-type natriuretic peptide (Bnp) were quantified using 
quantitative real-time PCR (qRT-PCR). Note that Anp and Bnp increased in control mice but were unaffected in AKO mice. n = 5 mice. (H–K) RNA was 
extracted from serum, adipose tissue, and cardiac tissue from AKO and control mice, and levels of mature miR-200a (H–J) or pri-miR-200a (K) were 
analyzed using qRT-PCR. Note that RSG increased levels of miR-200a in tissues from control mice, whereas RSG failed to increase the level of miR-
200a in serum, adipose tissue, and cardiac tissue in AKO mice. Pri-miR-200a was only increased in adipose tissue from RSG-treated WT mice. n = 5–8 
per group. Data are represented as mean ± SEM; *P < 0.05 according to 1-way ANOVA.
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RSG treatment revealed that interventricular septal wall thickness at end diastole and left ventricle posteri-
or wall thickness at end diastole were also attenuated in AKO mice compared with littermate control mice 
(Figure 6, D and E, and Table 1). Furthermore, both Anp and Bnp levels were blunted in cardiac tissue from 
AKO mice in response to RSG treatment (Figure 6, F and G). We next examined levels of  miR-200a in 
sera and adipose and cardiac tissue from AKO and control mice (Figure 6, H–J). While levels of  miR-200a 
significantly increased in all samples from control littermates following RSG treatment, no increases in lev-
els of  miR-200a were observed in AKO mice. Levels of  pri-miR-200a were significantly upregulated only 
in adipose tissue, but not in cardiac tissue, of  control WT mice and were not upregulated in either adipose 
or cardiac tissue in AKO mice (Figure 6K). The foregoing data were consistent with the hypothesis that 
adipose tissue is a major source of  circulating and cardiac miR-200a and that PPARγ signaling in adipose 
tissue is essential for cardiac hypertrophy in response to RSG treatment.
Discussion
There is an overall consensus that significant crosstalk occurs between adipose and cardiac tissue, but until 
now molecular players have remained elusive. Here, we reveal a direct signaling axis between adipocytes 
and cardiomyocytes that is guided by exosomal delivery of  miR-200a. We show that PPARγ activation in 
adipose tissue leads to expression and release of  miR-200a in exosomes into the circulatory system. Subse-
quently, miR-200a–containing exosomes target cardiomyocytes, in which miR-200a suppress expression of  
TSC1 and stimulates mTOR signaling to induce cardiac hypertrophy.
Secretion of  exosomes has emerged as an important paracrine mechanism for regulation of  cardiac 
hypertrophy between cardiac fibroblasts and cardiomyocytes. For example, a recent study showed that cardio-
myocytes are able to take up exosomes containing miR-21* that are secreted by cardiac fibroblasts, leading to 
cardiomyocyte hypertrophy by targeting SORBS2, SH3 domain–containing protein 2, and enigma homolog in 
cardiomyocytes (23). However, delivery of  exosomes to cardiomyocytes from other organs has proven elusive 
until now. In the present study, we provide in vitro evidence that miR-200a was transported in exosomes from 
adipocytes to cardiomyocytes, in which it targeted genes involved in regulating the mTOR pathway. However, 
direct evidence of  adipocyte-derived exosomes after RSG treatment as mediators of  cardiac hypertrophy 
remains to be established in vivo. In addition, it is very likely that there are other mediators in adipocyte-de-
rived exosomes after RSG treatment. Further studies are needed to identify these potential mediators.
miR-200a is abundantly expressed in adipose tissue, whereas it is barely expressed in vessels and heart 
at basal conditions (Supplemental Figure 1). Upon PPARγ activation, miR-200a transcription in adipose 
tissue, as measured by the levels of  pri-miR-200a, is activated about 6 folds, while levels of  pri-miR-200a 
in heart remain at basal levels. The exact mechanism for the observation remains to be determined, but 
it could be due to a lack of  an essential cofactor(s) in the heart that functions together with PPARγ to 
activate miR-200a transcription. Alternatively, it could be because of  a lack of  a transcriptional repres-
sor(s) that is restricted to the heart and is not present in adipose tissue that allows miR-200a transcription 
activation specifically in adipose tissue. It is interesting to note that miR-200a is upregulated in response 
to oxidative stress and in animal models of  diabetes (36). Epidemiological studies show that diabetes and 
insulin resistance are powerful predictors of  cardiovascular morbidity and mortality and are independent 
risk factors for death in patients with established heart failure (37–39). Animal models of  diabetes also 
show signs of  cardiac hypertrophy (40). Our data imply that miR-200a might be secreted from adipose tis-
sue and transported in exosomes that may target cardiac tissue and contribute to diabetic cardiomyopathy.
In this study, we identified TSC1, a repressor of  mTOR signaling, as a target of  miR-200a inhibition. 
Exogenous miR-200a overexpressed by adenovirus, or delivered by exosomes from adipocytes, downregu-
lated TSC1 in recipient cardiomyocytes and enhanced mTOR activation, leading to cardiomyocyte hyper-
trophy (Figure 4). Transfection of  an antagomir to miR-200a in adipocytes or cardiomyocytes was sufficient 
to attenuate hypertrophy (Figure 5). TSC1 has previously been shown to regulate cardiomyocyte size and 
cardiac remodeling through the mTOR pathway (32–34). It has been shown that mice in which TSC1 is 
specifically ablated in cardiomyocytes develop cardiac hypertrophy that leads to heart failure (35). Our data 
indicated a critical role for miR-200a in targeting TSC1 to result in cardiac hypertrophy. However, miRNAs 
function by complementary pairing of  their seed regions to 3ˇ-UTRs of  target mRNAs, and miR-200a has 
many potential targets in heart. Other examples of  miR-200a targets include FOG2 (friend of  GATA 2) and 
SIRT1 (silent information regulator 1) (41–44). SIRT1 is expressed in cardiomyocytes and has been shown 
to play a cardioprotective role following ischemia/reperfusion injury (45). FOG2 is a multitype zinc finger 
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protein that interacts with GATA factors and is essential for heart development and cardiac function. Car-
diomyocyte-specific deletion of  FOG2 leads to postnatal heart failure (46). In addition, FOG2 also directly 
binds to p85α, the regulatory subunit of  PI3K, and interferes with the formation of  the PI3K complex. 
As an inhibitor of  PI3K/Akt pathway, decreased FOG2 expression can activate PI3K/Akt signaling (41), 
which has a well-established role in cardiac hypertrophy (47–49). Specific roles of  SIRT1 and/or FOG2 in 
PPARγ activation–induced cardiac hypertrophy remain to be determined.
PPARγ is most highly expressed in adipose tissue and is also expressed at low levels in other tissues 
(1). Experiments with tissue-specific overexpression or knockout of  PPARγ have been crucial in help-
ing dissect specific effects of  PPARγ activity in different tissues. For example, mice with cardiac-specif-
ic overexpression of  PPARγ develop cardiomyopathy, suggesting a prohypertrophic action of  PPARγ 
in heart (13). However, mice with cardiomyocyte-specific ablation of  PPARγ develop hypertrophy in 
response to RSG (7), implying that systemic PPARγ activation causes cardiac hypertrophy through non-
cardiomyocytes. Our data demonstrated that RSG activated PPARγ signaling in adipose tissue to indi-
rectly lead to cardiac remodeling. Other examples highlighting PPARγ crosstalk between different tissues 
include activation of  PPARγ in brain, which contributes to thiazolidinedione-induced weight gain and 
whole-body energy balance (50). Additionally, PPARγ regulated adiponectin from adipocytes improves 
endothelial function in diabetic mice (51).
Adipose tissue is an important endocrine organ that plays a cardioprotective role by reducing lipotox-
ic effects in other peripheral tissues and by maintaining a healthy balance of  critical adipokines (15). Our 
data suggest that secretion of  exosomes from adipocytes is essential for induction of  cardiac hypertrophy in 
response to RSG, as inhibition of  exosome synthesis completely normalized Anp and Bnp mRNA levels (Fig-
ure 5, B and C). Notably, only a partial restoration of  normal Anp and Bnp mRNA levels was observed when 
PPARγ signaling was inhibited, implying that there are other factors in exosomes that can regulate cardiac 
hypertrophy independently of  PPARγ signaling. This is perhaps unsurprising, because many factors are likely 
to be secreted in exosomes from adipose tissue. For example, a recent microarray study revealed that mRNA 
and miRNAs other than miR-200a are found in exosomes derived from adipocytes (18). Factors other than 
oligonucleotides may also play a role. For example, recent studies have shown that, in response to inflamma-
tory stimuli, adipocytes secrete exosomes containing the proteins MFG-E8 and RBP4 (52).
In conclusion, our data suggest that one of  the direct links between PPARγ activation in adipocytes and 
cardiomyocyte hypertrophy is through mir-200a. However, the in vivo role of  miR-200a in the adipocyte-car-
diomyocyte axis remains to be determined. Our data suggest that exosome-mediated communication may 
have important clinical consequences in adipose biology and cardiomyopathy in the setting of  obesity.
Methods
Additional details are provided in the Supplemental Experimental Procedures.
Animals and RSG treatment. C57 BL/6 mice (strain code: 027) were purchased from Charles River. 
Fabp4-Cre [B6.Cg-Tg (Fabp4-cre) 1 Rev/J, stock no. 005069] and PPARG flox (B6.129-Ppargtm2Rev/J, 
stock no. 004584) mice were purchased from The Jackson Laboratory.
Fabp4-Cre mice (Cre driven by fatty acid–binding protein 4 [Fabp4] promoter) were crossed with floxed 
PPARG mice to obtain adipocyte-specific PPARγ-knockout (AKO) mice (homozygous floxed PPARG and 
Fabp4-Cre positive). AKO mice were bred with homozygous floxed PPARG mice to generate both AKO 
mice and littermate control mice (homozygous floxed PPARG and Fabp4-Cre negative) (53).
Male mice (8 to 10 weeks of  age, 6 to 8 mice per group) were treated with either regular chow or RSG 
chow for 4 weeks. RSG chow (0.01% RSG, Cayman Chemical) was produced by mixing RSG compound 
with D10012G rodent chow (Research Diet). Daily food consumption was 0.1 g chow/10 g body weight 
per day, which delivers a RSG dose of  10 mg/kg body weight per day.
Echocardiographic studies. Mice were anesthetized with 1% isoflurane and underwent echocardiography 
using a Vevo 2100 ultrasound system (VisualSonics, SonoSite FUJIFILM) with a 32- to 55-MHz linear 
transducer. Measurements of  heart rate (HR), left ventricular end-diastolic dimensions and left ventricu-
lar end-systolic dimensions, end-diastolic interventricular septal thickness, and left ventricle posterior wall 
thickness were determined from the left ventricle M-mode tracing. Percentage of  fractional shortening was 
used as an indicator of  systolic cardiac function. n = 6–8 mice were used for each group.
Cardiac hypertrophy calculation and histology. Mice were anesthetized with ketamine/xylazine and 
weighed to determine total body weight. Hearts were removed and left ventricles were weighed. Tibias 
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were dissected and measured. Left ventricular weight to body weight ratios (mg per g) and/or left ventric-
ular weight to tibia length ratios (mg per mm) were used as indicators of  cardiac hypertrophy. Hearts were 
fixed in PFA, dehydrated in 70% EtOH, and embedded in paraffin. Paraffin-embedded cardiac sections 
(8-μm thick) were stained with H&E as previously described (54). All chemicals were from Sigma-Aldrich.
Cell culture. Primary neonatal cardiomyocytes were isolated by using the Neonatal Cardiomyocyte Iso-
lation System (Worthington) according to the manufacturer’s instructions and were maintained in 80% 
DMEM/20% M199 medium supplemented with 10% horse serum, 5% FBS, and 1% penicillin/strepto-
mycin, with Brdu (100 μM) and ArAc (10 μM). Male Sprague-Dawley rats or C57BL/6 mice were used 
to extract primary cultures of  mature adipocytes. Briefly, epididymal fat pads were removed, minced, and 
digested with type I collagenase (Worthington) as described previously (55). Murine 3T3-L1 fibroblasts 
(a gift of  Jerrold M. Olefsky’s laboratory, Department of  Medicine, UCSD) were passaged in DMEM 
containing 10% fetal calf  serum (FCS). 3T3-L1 preadipocytes were differentiated into adipocytes when 
confluent by adding differentiation medium (DMEM containing 10% FBS, 1.0 μM dexamethasone, 0.5 
mM methylisobutylxanthine, 1.0 μg/ml insulin). After 2 days, the cells were transferred to adipocyte 
growth medium (DMEM containing 10% FBS, 1.0 μg/ml insulin) and fed every other day. Differentiation 
to mature adipocytes was confirmed by Oil Red O staining of  lipid vesicles (56). 3T3-L1–differentiated 
adipocytes and primary adipocytes were treated with RSG (Cayman Chemical), GW9662 (Cayman Chem-
ical), and GW4869 (Cayman Chemical) at the concentration 1 μM, 5 μM and 20 μM, respectively. Other 
reagents were from Sigma-Aldrich unless specified.
Coculture experiments. 3T3-L1 cells (1 × 106/well) were seeded into 6-well plates and induced into mature 
adipocytes before the coculture experiment. Primary neonatal cardiomyocytes (0.5 × 106) were seeded into 
the well inserts (0.4-μm diameter pore, Corning) and cultured in complete cardiomyocyte culture medium 
24 hours before coculture experiments. Before starting the coculture experiments, both adipocytes and car-
diomyocytes were washed with PBS. All coculture experiments were done in serum-free DMEM.
RNA isolation and quantitative RT-PCR. RNA was extracted from cultured cells or exosomes by using the 
TRIzol reagent (Life Technologies) according to the manufacturer’s instructions. For the isolation of miRNAs 
from serum or condition medium samples, 5 pg of synthetic C. elegans miRNA cel-miR-39 was added to each 
sample as a spike-in control for purification efficiency, and RNA was extracted using the miRNeasy Serum/
Plasma Kit (Qiagen) following the manufacturer’s instructions. Serum or conditioned medium was centrifuged 
at 2000 g for 10 minutes to remove cells before RNA isolation. Isolated RNAs were reverse transcribed into 
complementary DNA by using the TaqMan primer sets for miRs (Applied Biosystems) or Oligo (dT) primers 
for mRNAs. Real-time PCR was performed with the TaqMan Fast Universal PCR Master Mix (Applied Bio-
systems) or iQ SYBR Green Supermix (Bio-Rad) by using the TaqMan probes (Applied Biosystems) or specific 
primer pairs. Mature miR expression levels were normalized to the control snoRNA202 or Cel-miR-39 probes. 
Expression of mRNAs were normalized to Gapdh. Other PCR primers are listed in Supplemental Table 2.
Western blot analysis. Total protein was isolated from mouse hearts or neonatal rat cardiomyocytes, 
run on 4%–12% SDS-PAGE gel (Life Technologies), and transferred overnight on to PVDF membrane. 
Blots were blocked and incubated with the indicated primary antibodies, washed, probed with use of  
horseradish peroxidase–conjugated secondary antibodies in rabbit (1:5,000) or mouse (1:2,000) (Dako), 
and visualized by the ECL chemiluminescence system. Antibodies used for immunofluorescence and 
Western blotting are listed in Supplemental Table 1.
Immunofluorescence. Cardiomyocytes were fixed with 4% PFA, permeabilized with Triton X-100 (0.1%), and 
stained with phalloidin using Rhodamine-conjugated Phalloidin (Cytoskeleton) according to the manufacturer’s 
instructions. After staining, the samples were visualized by confocal microscopy (Olympus FV-1000).
Transfection and reporter assay. 3T3-L1 adipocytes were transfected with cel-miR-39 (10 nM final con-
centration) or miR-200a antagomir (50 nM final concentration) (mirVan miRNA Inhibitors, Ambion) 
using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s instructions. For 
luciferase assays, the luciferase reporter constructs containing the full-length TSC1 3ˇ-UTR (cloned from 
HEK293 genomic DNA) or 4x(ACAGTGTTA) “seed” binding sequences of  miR-200a from the 3ˇ-UTR 
of  pri-miR-reporter vector (Ambion) were used. HEK293 cells were cotransfected using Lipofectamine 
2000 (Life Technologies) with luciferase reporter plasmid DNA and miR-200a mimic (5 nM) or control oli-
gonucleotide (Life Technologies) as per manufacturer’s recommendations. Twenty-four hours after trans-
fection, luciferase activity was measured using the Luciferase assay system (Promega) and normalized to 
β-galactosidase activity assessed using o-nitrophenyl-β-D-galactopyranoside (Sigma-Aldrich).
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Adenovirus. miR-200a overexpression and antagomir adenoviruses were constructed by Welgen Inc. 
Briefly, mouse pri-miR-200a cDNA or miR-200a antagomir sequences (5ˇ-ACATCGTTACCAGACAGT-
GTTA-3ˇ) were cloned into pENT-CMV or pEQU6 vectors, respectively. The pENT-pri-miR-200a cDNA 
and pEQU6-antagomir were treated with LR Clonase II enzyme (Life Technologies) and ligated into the 
pAd-REP plasmid that contains the remaining adenovirus genome. The recombination products were 
amplified in E. coli (JM109 strain), and cosmid DNA was purified. The purified cosmid DNA (2 μg) was 
digested with Pac1 and transfected into HEK293 cells with Lipofectamine 2000 (Life Technologies) accord-
ing to manufacturer’s instructions. HEK293 cells were grown in 10% FBS DMEM and adenovirus plaques 
were seen 7 days after transfection. Empty pEntCMV shuttle vector or scramble RNA inserted in pEQU6 
served as the respective controls.
Exosome isolation. Exosomes were purified as described previously (29). Briefly, conditioned media from 
cultured adipocytes were subjected to sequential centrifugation steps of  300 g, 2,000 g, and 10,000 g before 
exosomes were pelleted at 100,000 g for 3 hours. Supernatant was discarded, and exosomes were washed 
and resuspended in PBS.
TEM experiment. Exosome were fixed (2% paraformaldehyde, 2% glutaraldehyde in 0.15 M sodium 
cacodylate buffer, pH 7.4) and stained overnight in 1% osmium tetroxide, 0.8% potassium ferrocyanide. 
The following day, exosomes were stained for 2 hours in 2% uranyl acetate and subsequently dehydrated in 
a series of  ethanol and acetone washes. Exosomes were embedded in Durcupan resin (EMD), and ultrathin 
sections (60–70 nm) were stained with lead citrate. Electron micrographs were recorded using a JEOL 
1200EX electron microscope operated at 80 kV. All chemicals were from Sigma-Aldrich.
Statistics. Data are expressed as mean ± SEM and were examined by using 2-tailed Student’s t test or 
ANOVA for comparisons among groups as indicated. P < 0.05 was considered statistically significant.
Study approval. All animal procedures were performed in accordance with National Institutes of  Health 
guidelines and were approved by the UCSD Animal Care and Use Committee. UCSD has an Animal Wel-
fare Assurance (A3033-01) on file with the Office of  Laboratory Animal Welfare and is fully accredited by 
AAALAC International.
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